Celgene to hold an analyst call on October 18, 2016 at 9 a.m. ET
SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ:CELG) today announced that the data from a
randomized, double-blind, multicenter, exploratory phase Ib study
evaluating the effects of oral GED-0301 (mongersen) on both endoscopic
and clinical outcomes in patients with active Crohn's disease were
accepted as a late breaking abstract at the United European
Gastroenterology Week. The data are to be presented on October 18, 2016
at 6:27 a.m. ET.
Celgene will hold a conference call for the investment community to
discuss the data on October 18, 2016, at 9 a.m. ET. The conference call
will be available by webcast at www.celgene.com.
An audio replay of the call will be available from noon ET October 18,
2016, until midnight ET October 25, 2016. To access the replay in the
U.S., dial (855) 859-2056; outside the U.S. dial (404) 537-3406. The
participant passcode is 87802096.
GED-0301 (mongersen) is an investigational compound that is not approved
for any use in any country.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005447/en/
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations
Brian Gill, 908-673-9530
Source: Celgene Corporation
News Provided by Acquire Media